Zomedica Historical Balance Sheet

ZOM Stock

USD 0.12 0.01 7.69%

Trend analysis of Zomedica Pharmaceuticals Corp balance sheet accounts such as Total Assets of 305.7 M, Other Current Liab of 91.5 K, Total Current Liabilities of 10.9 M or Total Stockholder Equity of 289.8 M provides information on Zomedica Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Zomedica Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Zomedica Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Zomedica Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Zomedica Pharmaceuticals is a good buy for the upcoming year.

Zomedica Pharmaceuticals Inventory

6.19 Million

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

About Zomedica Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Zomedica Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Zomedica Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Zomedica Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Zomedica currently owns. An asset can also be divided into two categories, current and non-current.

Zomedica Pharmaceuticals Balance Sheet Chart

At this time, Zomedica Pharmaceuticals' Other Assets are very stable compared to the past year. As of the 24th of January 2025, Cash And Short Term Investments is likely to grow to about 109.3 M, while Net Debt is likely to drop (9.7 M).

Total Assets Total Current Liabilities Total Stockholder Equity Non Current Assets Total

Add Fundamental

Total Assets

Total assets refers to the total amount of Zomedica Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Zomedica Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Zomedica Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Zomedica Pharmaceuticals Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Most accounts from Zomedica Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Zomedica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

	2022	2023	2024	2025 (projected)
Total Stockholder Equity	267.4M	240.0M	276.0M	289.8M
Total Current Liabilities	7.8M	9.0M	10.4M	10.9M

Total Stockholder Equity Total Current Liabilities

Zomedica Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Common Stock	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Current Liabilities Total	Property Plant And Equipment Gross	Short Long Term Debt	Short Term Debt	Intangible Assets
Total Assets		-0.36	0.93	1.0	-0.45	-0.96	0.51	0.96	0.47	0.21	0.93	0.82	0.88	0.94	0.93	0.99	0.78	-0.14	1.0	0.81	0.91	0.52	0.82	0.83	0.95	0.96
Other Current Liab	-0.36		-0.23	-0.37	0.04	0.23	-0.05	-0.38	0.38	0.77	-0.28	-0.17	-0.1	-0.29	-0.34	-0.29	-0.14	0.18	-0.33	-0.21	-0.23	0.08	-0.23	-0.26	-0.31	-0.35
Total Current Liabilities	0.93	-0.23		0.93	-0.16	-0.96	0.22	0.98	0.46	0.3	0.75	0.92	0.88	0.78	0.98	0.96	0.79	-0.12	0.91	0.94	1.0	0.44	0.94	0.83	0.9	0.98
Total Stockholder Equity	1.0	-0.37	0.93		-0.45	-0.95	0.51	0.96	0.46	0.19	0.93	0.82	0.86	0.94	0.92	0.99	0.78	-0.14	1.0	0.81	0.91	0.51	0.82	0.83	0.94	0.96
Net Debt	-0.45	0.04	-0.16	-0.45		0.36	-1.0	-0.17	-0.18	-0.13	-0.75	0.0	-0.36	-0.72	-0.09	-0.42	-0.28	0.07	-0.5	0.05	-0.11	-0.51	0.04	-0.42	-0.41	-0.22
Retained Earnings	-0.96	0.23	-0.96	-0.95	0.36		-0.42	-0.93	-0.41	-0.31	-0.86	-0.83	-0.92	-0.88	-0.92	-0.97	-0.83	0.13	-0.94	-0.85	-0.94	-0.59	-0.85	-0.91	-0.94	-0.93
Cash	0.51	-0.05	0.22	0.51	-1.0	-0.42		0.24	0.22	0.15	0.79	0.07	0.42	0.77	0.16	0.48	0.31	-0.08	0.56	0.03	0.17	0.53	0.03	0.47	0.46	0.29
Non Current Assets Total	0.96	-0.38	0.98	0.96	-0.17	-0.93	0.24		0.45	0.17	0.78	0.9	0.84	0.8	0.99	0.96	0.76	-0.13	0.94	0.92	0.98	0.39	0.93	0.78	0.91	0.99
Non Currrent Assets Other	0.47	0.38	0.46	0.46	-0.18	-0.41	0.22	0.45		0.67	0.42	0.51	0.52	0.43	0.46	0.48	0.31	0.07	0.5	0.45	0.44	0.41	0.44	0.13	0.49	0.47
Other Assets	0.21	0.77	0.3	0.19	-0.13	-0.31	0.15	0.17	0.67		0.22	0.31	0.43	0.22	0.19	0.27	0.44	0.13	0.21	0.18	0.3	0.43	0.16	0.21	0.3	0.16
Cash And Short Term Investments	0.93	-0.28	0.75	0.93	-0.75	-0.86	0.79	0.78	0.42	0.22		0.6	0.81	1.0	0.72	0.91	0.7	-0.14	0.94	0.58	0.72	0.63	0.58	0.8	0.88	0.79
Other Stockholder Equity	0.82	-0.17	0.92	0.82	0.0	-0.83	0.07	0.9	0.51	0.31	0.6		0.74	0.63	0.92	0.85	0.68	0.21	0.8	0.9	0.92	0.29	0.91	0.65	0.76	0.9
Total Liab	0.88	-0.1	0.88	0.86	-0.36	-0.92	0.42	0.84	0.52	0.43	0.81	0.74		0.83	0.84	0.91	0.7	-0.16	0.88	0.79	0.85	0.81	0.77	0.9	0.96	0.83
Total Current Assets	0.94	-0.29	0.78	0.94	-0.72	-0.88	0.77	0.8	0.43	0.22	1.0	0.63	0.83		0.75	0.93	0.72	-0.14	0.96	0.61	0.75	0.62	0.61	0.81	0.9	0.82
Net Receivables	0.93	-0.34	0.98	0.92	-0.09	-0.92	0.16	0.99	0.46	0.19	0.72	0.92	0.84	0.75		0.94	0.72	-0.13	0.91	0.96	0.98	0.39	0.96	0.77	0.88	0.99
Common Stock Shares Outstanding	0.99	-0.29	0.96	0.99	-0.42	-0.97	0.48	0.96	0.48	0.27	0.91	0.85	0.91	0.93	0.94		0.79	-0.12	0.99	0.85	0.94	0.56	0.85	0.87	0.96	0.96
Other Current Assets	0.78	-0.14	0.79	0.78	-0.28	-0.83	0.31	0.76	0.31	0.44	0.7	0.68	0.7	0.72	0.72	0.79		-0.03	0.74	0.55	0.79	0.4	0.56	0.71	0.79	0.7
Common Stock	-0.14	0.18	-0.12	-0.14	0.07	0.13	-0.08	-0.13	0.07	0.13	-0.14	0.21	-0.16	-0.14	-0.13	-0.12	-0.03		-0.14	-0.12	-0.12	-0.14	-0.12	-0.2	-0.16	-0.14
Net Tangible Assets	1.0	-0.33	0.91	1.0	-0.5	-0.94	0.56	0.94	0.5	0.21	0.94	0.8	0.88	0.96	0.91	0.99	0.74	-0.14		0.8	0.89	0.55	0.81	0.82	0.94	0.95
Property Plant And Equipment Net	0.81	-0.21	0.94	0.81	0.05	-0.85	0.03	0.92	0.45	0.18	0.58	0.9	0.79	0.61	0.96	0.85	0.55	-0.12	0.8		0.94	0.33	1.0	0.71	0.76	0.94
Accounts Payable	0.91	-0.23	1.0	0.91	-0.11	-0.94	0.17	0.98	0.44	0.3	0.72	0.92	0.85	0.75	0.98	0.94	0.79	-0.12	0.89	0.94		0.39	0.95	0.81	0.87	0.97
Non Current Liabilities Total	0.52	0.08	0.44	0.51	-0.51	-0.59	0.53	0.39	0.41	0.43	0.63	0.29	0.81	0.62	0.39	0.56	0.4	-0.14	0.55	0.33	0.39		0.3	0.7	0.72	0.39
Property Plant And Equipment Gross	0.82	-0.23	0.94	0.82	0.04	-0.85	0.03	0.93	0.44	0.16	0.58	0.91	0.77	0.61	0.96	0.85	0.56	-0.12	0.81	1.0	0.95	0.3		0.7	0.76	0.95
Short Long Term Debt	0.83	-0.26	0.83	0.83	-0.42	-0.91	0.47	0.78	0.13	0.21	0.8	0.65	0.9	0.81	0.77	0.87	0.71	-0.2	0.82	0.71	0.81	0.7	0.7		0.87	0.78
Short Term Debt	0.95	-0.31	0.9	0.94	-0.41	-0.94	0.46	0.91	0.49	0.3	0.88	0.76	0.96	0.9	0.88	0.96	0.79	-0.16	0.94	0.76	0.87	0.72	0.76	0.87		0.88
Intangible Assets	0.96	-0.35	0.98	0.96	-0.22	-0.93	0.29	0.99	0.47	0.16	0.79	0.9	0.83	0.82	0.99	0.96	0.7	-0.14	0.95	0.94	0.97	0.39	0.95	0.78	0.88

Click cells to compare fundamentals

Zomedica Pharmaceuticals Account Relationship Matchups

Zomedica Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	66.1M	280.4M	279.6M	253.2M	291.2M	305.7M
Other Current Liab	1.2M	45.1K	(1.0M)	107K	96.3K	91.5K
Total Current Liabilities	2.0M	4.3M	7.8M	9.0M	10.4M	10.9M
Total Stockholder Equity	51.1M	270.9M	267.4M	240.0M	276.0M	289.8M
Net Debt	(60.1M)	(193.6M)	(25.7M)	(10.2M)	(9.2M)	(9.7M)
Retained Earnings	(69.0M)	(119.4M)	(136.4M)	(170.9M)	(153.8M)	(146.1M)
Cash	62.0M	195.0M	27.4M	13.0M	14.9M	28.1M
Non Current Assets Total	3.3M	80.0M	156.1M	153.3M	176.3M	185.1M
Non Currrent Assets Other	1M	659.1K	453K	1.1M	1.2M	1.3M
Cash And Short Term Investments	62.0M	195.0M	115.1M	90.5M	104.1M	109.3M
Liabilities And Stockholders Equity	66.1M	280.4M	279.6M	253.2M	291.2M	305.7M
Other Stockholder Equity	2.8M	9.3M	23.7M	29.9M	34.4M	36.1M
Total Liab	15.1M	9.5M	12.2M	13.2M	15.2M	15.9M
Total Current Assets	62.9M	200.4M	123.5M	99.9M	114.9M	120.6M
Net Receivables	146.2K	765.5K	1.9M	2.2M	2.5M	2.7M
Common Stock Shares Outstanding	364.4M	956.5M	979.9M	979.9M	1.1B	1.2B
Other Current Assets	727.8K	1.8M	3.8M	2.1M	2.4M	1.4M
Accumulated Other Comprehensive Income	459.6K	1.7K	(843K)	48K	43.2K	59.2K
Common Stock	38.6M	104.8M	381.0M	381.0M	342.9M	325.7M
Net Tangible Assets	(10.4M)	50.7M	194.1M	161.6M	185.9M	195.1M
Property Plant And Equipment Net	1.9M	2.5M	9.2M	25.3M	29.1M	30.5M
Accounts Payable	1.2M	3.2M	6.7M	7.7M	8.8M	9.3M
Common Stock Total Equity	38.6M	459.6	381.0M	381.0M	438.1M	460.0M
Retained Earnings Total Equity	(52.1M)	(69.0M)	(119.4M)	(136.4M)	(122.8M)	(116.6M)
Non Current Liabilities Total	13.0M	5.2M	4.4M	4.1M	4.8M	3.3M
Property Plant And Equipment Gross	583.01	3.4M	10.4M	27.3M	31.4M	33.0M
Short Term Debt	780.1K	829.7K	1.3M	916K	1.1M	1.1M
Intangible Assets	376.6K	33.5M	41.8M	55.4M	63.7M	66.9M
Property Plant Equipment	1.8M	583.0K	2.5M	6.8M	7.8M	8.2M
Cash And Equivalents	510.6K	62.0M	195.0M	27.4M	31.5M	46.1M
Capital Surpluse	3.6M	14.8M	9.3M	23.7M	27.2M	28.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:

How To Invest In Zomedica

Details

Is Zomedica Stock a good investment?

Details

What is Zomedica Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.06)

Revenue Per Share

0.027

Quarterly Revenue Growth

0.018

Return On Assets

(0.09)

Return On Equity

(0.24)

The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zomedica Historical Balance Sheet

Zomedica Pharmaceuticals Inventory

6.19 Million

About Zomedica Balance Sheet Analysis

Zomedica Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Non Current Assets Total

Zomedica Pharmaceuticals balance sheet Correlations

Zomedica Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zomedica Pharmaceuticals balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Current Liabilities
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Retained Earnings	- 0.96	Total Assets
Retained Earnings	- 0.95	Total Stockholder Equity
Short Term Debt	- 0.94	Retained Earnings